Eli Lilly Stock Gets Downgraded. It Faces Stiff Headwinds After Strong Run-Up.

Core Viewpoint - Eli Lilly, the manufacturer of Zepbound and Mounjaro, is expected to encounter significant price competition in the upcoming year according to HSBC [1] Company Summary - Eli Lilly is facing challenges in maintaining pricing power for its products Zepbound and Mounjaro due to anticipated competitive pressures [1]